Untitled Page

CTU - Current Research

SPRINT: SYSTOLIC BLOOD PRESSURE INTERVENTION TRIAL (Ongoing)

Principal Investigator: Marie “Tonette” Krousel-Wood, MD, MSPH
Sub Investigators: Richard Diechmann, MD, and Patricia Rooney, MD
Classification: Health Services Research/Internal Medicine
Phase/Type: V
IRB #: 2011.206.A
Sponsor: National Institutes of Health (NIH)

Contact: Donnalee Trapani, LPN, CCRP; (504) 894-2864; dtrapani@ochsner.org  

 

A MULTI-CENTER, RANDOMIZED, CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF THE KXL SYSTEM WITH VIBEX (RIBOFLAVIN OPHTHALMIC SOLUTION) FOR CORNEAL COLLAGEN CROSS-LINKING IN EYES WITH KERATOCONUS OR CORNEAL ECTASIA AFTER REFRACTIVE SURGERY (Ongoing)

Principal Investigator: Pulin Shah, MD
Sub Investigator: Ginny Kullman, MD
Classification: Ophthalmology
Phase/Type: III
Sponsor: American-Europeon Congress of Ophthalmic Surgery (ACOS)

Contact: Donnalee Trapani, LPN, CCRP; (504) 894-2864; dtrapani@ochsner.org

 

OBESITY HYPOVENTIALTION SYNDROME PREVALENCE STUDY (Ongoing)

Principal Investigator: Stuart Busby, MD
Sub Investigators: Liudmila Lysenko, MD, and Victoria Brandt, MD
Classification: Sleep Medicine 
Phase/Type: Observational
Sponsor: Respironics, Inc., a Philips Healthcare Company

Contact: Cheryl Sanders, MN, RN, CCRC; (504) 897-5883; Cheryl.Sanders@ochsner.org

 

SOLSTICE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ELAGOLIX IN SUBJECTS WITH MODERATE TO SEVERE ENDOMETRIOSIS-ASSOCIATED PAIN (Ongoing)

Principal Investigator: Rajiv Gala, MD
Sub Investigators: Veronica Gillispie, MD, FACOG, and Leise Knoepp, MD
Classification: Women's Health/Gynecology 
Phase/Type: III
Sponsor: AbbVie

Contact: Cheryl Sanders, MN, RN, CCRC; (504) 897-5883; Cheryl.Sanders@ochsner.org

 

TRIALNET: NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES (Ongoing)

Principal Investigator: Cielo Alleyn, MD
Sub Investigators: Monisha Chadha, MD, and Paige Robichaux, RN, CDE
Classification: Endocrinology 
Phase/Type: Diagnostic
Sponsor: National Institutes of Health (NIH)

Contact: Michael Lizanna, BSN, RN; (504) 897-5882; Michael.Lizanna@ochsner.org

 

A PHASE 3 MULTICENTER, TWO-PHASE, MULTI-DOSE, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ZS (MICROPOROUS, FRACTIONATED, PROTONATED ZIRCONIUM SILICATE), AN ORAL SORBENT, IN SUBJECTS WITH MILD TO MODERATE HYPERKALEMIA (Closed)

Principal Investigator: Fred Husserl, MD
Sub Investigators: Pierre Blemur, MD
Classification: Nephrology
Phase/Type: III
Sponsor: ZS Pharma, Inc. 

 

OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF INTRAVENOUS CARBAMAZEPINE AS SHORT-TERM REPLACEMENT OF ORAL CARBAMAZEPINE IN ADULT PATIENTS WITH EPILEPSY (Closed)

Principal Investigator: Eugene Ramsay, MD
Sub Investigators: Bridget Bagert, MD, Frank Oser, MD, Terence D'Souza, MD, Fawad Khan, MD, Uma Menon, MD, Shelley Huff, MD, and Fred Abi-Samra, MD
Classification: Neurology
Phase/Type: III
Sponsor: Lundbeck Inc.

 

THE IMPACT OF A HUMAN PAPILLOMAVIRUS EDUCATIONAL MEDIA INTERVENTION STUDY (EIS) ON THE KNOWLEDGE, HEALTH BELIEFS, AND HEALTH BEHAVIORS AND INCREASING THE USE OF GARDASIL VACCINE IN WOMEN OF COLOR AGES 18-45 (Ongoing)

Principal Investigator: Charlotte S. Hurst, PhD, RN, CNM (Dillard University)
Sub Investigators: Veronica Gillispie, MD, FACOG (Ochsner), and Michael Hagensee, MD, PhD (LSUHSC)
Classification: Women's Health/Gynecology 
Phase/Type: Observational
Sponsor: National Institutes of Health (NIH)

Contact: Cheryl Sanders, MN, RN, CCRC; (504) 897-5883; Cheryl.Sanders@ochsner.org

 

PREFER-MS: A 12-MONTH, PROSPECTIVE, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE PATIENT RETENTION OF FINGOLIMOD VS. APPROVED FIRST-LINE DISEASE MODIFYING THERAPIES IN ADULTS WHO ARE IN EARLY STAGES OF TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS (Ongoing)

Principal Investigator: Amparo Gutierrez, MD (LSUHSC)
Sub Investigator: Jesus Lovera, MD (LSUHSC)
Classification: Neurology 
Phase/Type: III
Sponsor: Novartis 

Contact: Cheryl Sanders, MN, RN, CCRC; (504) 897-5883; Cheryl.Sanders@ochsner.org

 

A PHASE 2, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SRM003 (VASCUGEL) IN THE TREATMENT OF SUBJECTS WITH VASCULAR INJURY RESULTING FROM ARTERIOVENOUS GRAFT SURGERY FOR HEMODIALYSIS ACCESS (Ongoing)

Principal Investigator: Efrain Reisin, MD (LSUHSC)
Sub Investigators: Mihran Naljayan, MD, Oksana Nimkevych, MD, Jonathan Owen, MD, Bruce Torrance, MD, Erwin Aguilar, PharmD, and Sean Barry (LSUHSC)
Classification: Nephrology
Phase/Type: II
Sponsor: Shire Regenerative Medicine 

Contact: Cheryl Sanders, MN, RN, CCRC; (504) 897-5883; Cheryl.Sanders@ochsner.org

 

A PHASE 2, SINGLE-BLIND, RANDOMIZED, CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SRM003 (VASCUGEL) IN IMPROVING THE RATE OF ARTERIOVENOUS FISTULA MATURATION AND USE IN SUBJECTS UNDERGOING SURGERY FOR CREATION OF AN ARTERIOVENOUS FISTULA FOR HEMODIALYSIS ACCESS (Ongoing)

Principal Investigator: Efrain Reisin, MD (LSUHSC)
Sub Investigators: Mihran Naljayan, MD, Oksana Nimkevych, MD, Jonathan Owen, MD, Bruce Torrance, MD, Erwin Aguilar, PharmD, and Sean Barry (LSUHSC)
Classification: Nephrology 
Phase/Type: II
Sponsor: Shire Regenerative Medicine 

Contact: Cheryl Sanders, MN, RN, CCRC; (504) 897-5883; Cheryl.Sanders@ochsner.org

 

AN OPEN-LABEL, PILOT, PHASE 2 STUDY TO INVESTIGATE THE PRELIMINARY EFFICACY AND SAFETY OF ALDOXORUBICIN IN SUBJECTS WITH UNRESECTABLE GLIOBLASTOMA MULTIFORME WHOSE TUMORS HAVE PROGRESSED FOLLOWING PRIOR TREATMENT WITH SURGERY, RADIATION, AND TEMOZOLOMIDE (Ongoing)

Principal Investigator: Brian Boulmay, MD (LSUHSC)
Sub Investigator: Robert Ramirez, DO (LSUHSC)
Classification: Oncology 
Phase/Type: II
Sponsor: CytRx Corporation

Contact: Michael Lizanna, BSN, RN; (504) 897-5882; Michael.Lizanna@ochsner.org

 

menu top
Left Menu Home Small
Left Menu CTU Small
Left Menu Leadership Small
Left Menu Give Small
Left Menu Contact Small
Left Menu UQ
menu bottom
Untitled Page